Charles River Laboratories International, Inc. (CRL) stock
CRLNYSEServices-Commercial Physical & Biological ResearchFiscal year ends December 27
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30225% above fair value
$333.25+1.09 (+0.33%)
Close on Nov 18, 2026Market cap $15.91BP/E –Yield –
Charles River Laboratories International operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Charles River Laboratories International's operating income for the twelve months ending Jun 27, 2026 was $90.14M, down 27.6% year over year. For fiscal 2025 it was $25.16M, down 88.9% from the year before. Over ten years it grew -19.0% a year on average. The highest annual figure on record is $650.98M in fiscal 2022.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $25.16M | -88.9% |
| FY2024 | Dec 28, 2024 | $227.35M | -63.2% |
| FY2023 | Dec 30, 2023 | $617.26M | -5.2% |
| FY2022 | Dec 31, 2022 | $650.98M | +10.4% |
| FY2021 | Dec 25, 2021 | $589.86M | +36.3% |
| FY2020 | Dec 26, 2020 | $432.73M | +23.2% |
| FY2019 | Dec 28, 2019 | $351.15M | +6.0% |
| FY2018 | Dec 29, 2018 | $331.38M | +15.0% |
| FY2017 | Dec 30, 2017 | $288.28M | +21.4% |
| FY2016 | Dec 31, 2016 | $237.55M | +15.1% |
| FY2015 | Dec 26, 2015 | $206.45M | +16.2% |
| FY2014 | Dec 27, 2014 | $177.67M | +17.4% |
| FY2013 | Dec 28, 2013 | $151.40M | -8.7% |
| FY2012 | Dec 29, 2012 | $165.77M | -4.9% |
| FY2011 | Dec 31, 2011 | $174.31M | – |
| FY2010 | Dec 25, 2010 | -$298.51M | -276.0% |
| FY2009 | Dec 26, 2009 | $169.61M | – |
| FY2008 | Dec 27, 2008 | -$451.84M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 27, 2026 | $119.89M | +19.7% |
| Q1 FY2026 | Mar 28, 2026 | $119.90M | +60.6% |
| Q4 FY2025 | Dec 27, 2025 | -$283.44M | – |
| Q3 FY2025 | Sep 27, 2025 | $133.80M | +14.0% |
| Q2 FY2025 | Jun 28, 2025 | $100.13M | -34.0% |
| Q1 FY2025 | Mar 29, 2025 | $74.67M | -40.7% |
| Q4 FY2024 | Dec 28, 2024 | -$167.69M | -226.2% |
| Q3 FY2024 | Sep 28, 2024 | $117.41M | -22.5% |
| Q2 FY2024 | Jun 29, 2024 | $151.65M | -8.1% |
| Q1 FY2024 | Mar 30, 2024 | $125.98M | -25.0% |
| Q4 FY2023 | Dec 30, 2023 | $132.92M | -18.9% |
| Q3 FY2023 | Sep 30, 2023 | $151.50M | +0.3% |
| Q2 FY2023 | Jul 1, 2023 | $164.95M | -12.0% |
| Q1 FY2023 | Apr 1, 2023 | $167.89M | +12.8% |
| Q4 FY2022 | Dec 31, 2022 | $163.81M | -5.2% |
| Q3 FY2022 | Sep 24, 2022 | $150.98M | -3.1% |
| Q2 FY2022 | Jun 25, 2022 | $187.41M | +36.2% |
| Q1 FY2022 | Mar 26, 2022 | $148.78M | +20.3% |
| Q4 FY2021 | Dec 25, 2021 | $172.81M | +34.0% |
| Q3 FY2021 | Sep 25, 2021 | $155.80M | +17.4% |
| Q2 FY2021 | Jun 26, 2021 | $137.55M | +79.2% |
| Q1 FY2021 | Mar 27, 2021 | $123.70M | +31.2% |
| Q4 FY2020 | Dec 26, 2020 | $128.93M | +18.5% |
| Q3 FY2020 | Sep 26, 2020 | $132.75M | +43.0% |
| Q2 FY2020 | Jun 27, 2020 | $76.77M | -3.8% |
| Q1 FY2020 | Mar 28, 2020 | $94.28M | +35.1% |
| Q4 FY2019 | Dec 28, 2019 | $108.79M | +6.2% |
| Q3 FY2019 | Sep 28, 2019 | $92.80M | +10.0% |
| Q2 FY2019 | Jun 29, 2019 | $79.77M | +4.0% |
| Q1 FY2019 | Mar 30, 2019 | $69.79M | +2.9% |
| Q4 FY2018 | Dec 29, 2018 | $102.48M | +63.1% |
| Q3 FY2018 | Sep 29, 2018 | $84.36M | +13.9% |
| Q2 FY2018 | Jun 30, 2018 | $76.71M | -6.1% |
| Q1 FY2018 | Mar 31, 2018 | $67.83M | -2.7% |
| Q4 FY2017 | Dec 30, 2017 | $62.83M | -9.1% |
| Q3 FY2017 | Sep 30, 2017 | $74.06M | +26.0% |
| Q2 FY2017 | Jul 1, 2017 | $81.69M | – |
| Q1 FY2017 | Apr 1, 2017 | $69.71M | – |
| Q4 FY2016 | Dec 31, 2016 | $69.09M | – |
| Q3 FY2016 | Sep 24, 2016 | $58.80M | – |
See a number that looks wrong?